570 related articles for article (PubMed ID: 17317619)
1. Safety of intravenous immunoglobulin (IVIG) therapy.
Katz U; Achiron A; Sherer Y; Shoenfeld Y
Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin: adverse effects and safe administration.
Orbach H; Katz U; Sherer Y; Shoenfeld Y
Clin Rev Allergy Immunol; 2005 Dec; 29(3):173-84. PubMed ID: 16391392
[TBL] [Abstract][Full Text] [Related]
3. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
4. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
Katz U; Kishner I; Magalashvili D; Shoenfeld Y; Achiron A
Autoimmunity; 2006 Sep; 39(6):513-7. PubMed ID: 17060031
[TBL] [Abstract][Full Text] [Related]
5. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
[TBL] [Abstract][Full Text] [Related]
6. [Adverse effects of administration of intravenous human immunoglobulins].
Bednarík J; Kadanka Z
Cas Lek Cesk; 1999 Nov; 138(21):647-9. PubMed ID: 10746020
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
[TBL] [Abstract][Full Text] [Related]
8. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy.
Daphnis E; Stylianou K; Alexandrakis M; Xylouri I; Vardaki E; Stratigis S; Kyriazis J
Nephron Clin Pract; 2007; 106(4):c143-8. PubMed ID: 17596722
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.
Sapir T; Blank M; Shoenfeld Y
Ann N Y Acad Sci; 2005 Jun; 1051():743-78. PubMed ID: 16127014
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulins in neurological disorders: safety issues.
Eibl MM
Neurol Sci; 2003 Oct; 24 Suppl 4():S222-6. PubMed ID: 14598047
[TBL] [Abstract][Full Text] [Related]
11. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
[TBL] [Abstract][Full Text] [Related]
12. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation.
Chapman SA; Gilkerson KL; Davin TD; Pritzker MR
Ann Pharmacother; 2004 Dec; 38(12):2059-67. PubMed ID: 15536143
[TBL] [Abstract][Full Text] [Related]
13. Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
Barsheshet A; Marai I; Appel S; Zimlichman E
Ann N Y Acad Sci; 2007 Sep; 1110():315-8. PubMed ID: 17911446
[TBL] [Abstract][Full Text] [Related]
14. Acute renal failure resulting from intravenous immunoglobulin therapy.
Wajanaponsan N; Cheng SF
Hawaii Med J; 2004 Sep; 63(9):266-7. PubMed ID: 15540524
[TBL] [Abstract][Full Text] [Related]
15. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of adverse events when changing intravenous immunoglobulin preparations.
Ameratunga R; Sinclair J; Kolbe J
Clin Exp Immunol; 2004 Apr; 136(1):111-3. PubMed ID: 15030521
[TBL] [Abstract][Full Text] [Related]
17. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature.
Vecchietti G; Kerl K; Prins C; Kaya G; Saurat JH; French LE
Arch Dermatol; 2006 Feb; 142(2):213-7. PubMed ID: 16490849
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy.
Ahsan N
J Nephrol; 1998; 11(3):157-61. PubMed ID: 9650125
[TBL] [Abstract][Full Text] [Related]
19. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion.
Welles CC; Tambra S; Lafayette RA
Am J Kidney Dis; 2010 Jan; 55(1):148-51. PubMed ID: 19628320
[TBL] [Abstract][Full Text] [Related]
20. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience.
Vo AA; Cam V; Toyoda M; Puliyanda DP; Lukovsky M; Bunnapradist S; Peng A; Yang K; Jordan SC
Clin J Am Soc Nephrol; 2006 Jul; 1(4):844-52. PubMed ID: 17699296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]